SCHEMBL23328129

SCHEMBL23328129

Cc1cccc(Cl)c1-c1cc(Br)c2ccncc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.40
SRC P12931 7/20 0.40
ABL1 P00519 1/20 0.38
GRIA1 P42261 1/20 0.36
CACNG8 Q8WXS5 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
IMPDH2 P12268 2/20 0.34
PRKCZ Q05513 1/20 0.34
PRKD2 Q9BZL6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30175684 1.00 PDE2A (0.40) PDE2ASRCABL1GRIA1CACNG8
SCHEMBL23301129 0.84 PRKCZ (0.43) SRCABL1LMNACYP1A2CYP3A4
SCHEMBL29897440 0.84 PRKCZ (0.43) SRCABL1LMNACYP1A2CYP3A4
SCHEMBL29897338 0.81 SRC (0.44) SRCABL1GRIA1CACNG8
SCHEMBL23301167 0.81 SRC (0.44) SRCABL1GRIA1CACNG8
SCHEMBL23301569 0.78 ABL1 (0.42) PDE2ASRCABL1GRIA1CACNG8
SCHEMBL29897393 0.78 ABL1 (0.42) PDE2ASRCABL1GRIA1CACNG8
SCHEMBL23328123 0.74 PRKCZ (0.46) PRKCZPRKD2
SCHEMBL23328161 0.73 PRKCZ (0.55) PRKCZPRKD2
SCHEMBL23302002 0.73 SRC (0.48) SRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 US disclosed
WO-2021084265-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 WO disclosed
WO-2021084264-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS SIK2, SIK3, SIK1 PDE2A 3038/4885SRC 272/4885ABL1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.